---
title: "ARA 290 (Cibinetide)"
canonical_url: https://peptidelibrary.app/library/ara-290
description: "Helix-B surface peptide (cibinetide) that selectively activates the innate repair receptor without stimulating erythropoiesis. Investigational for small-fiber neuropathy and sarcoidosis."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# ARA 290 (Cibinetide)

ARA 290 (Cibinetide), also called PHβSP or Innate Repair Receptor agonist, is an innate Repair Receptor agonist. ARA 290, also called cibinetide, is an eleven-amino-acid peptide corresponding to a helix B surface region of erythropoietin.

Helix-B surface peptide (cibinetide) that selectively activates the innate repair receptor without stimulating erythropoiesis. Investigational for small-fiber neuropathy and sarcoidosis.

Also known as: PHβSP, Innate Repair Receptor agonist.

Categories: Muscle/Recovery.

## Classification

- Type: Innate Repair Receptor agonist / investigational
- Mechanism class: Innate Repair Receptor Agonist
- Development stage: In clinical development
- Regulatory class: Investigational, not FDA-approved

## Mechanism

ARA 290, also called cibinetide, is an eleven-amino-acid peptide corresponding to a helix B surface region of erythropoietin. Erythropoietin has two distinct activities: haematopoiesis through the classical EPO receptor homodimer, and tissue protection through a separate heterodimeric innate repair receptor formed by EPOR paired with the beta common receptor CD131. ARA 290 was designed to engage only the second. It binds the innate repair receptor to trigger anti-inflammatory and cytoprotective signalling without stimulating erythropoiesis, avoiding the thrombotic and haematocrit effects that limit EPO itself. It has been studied in small-fibre neuropathy and sarcoidosis and is investigational.

Targets: Innate repair receptor (EPOR–βc).

Origin: Synthetic EPO helix-B peptide.

## Properties

- Sequence: pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
- Molecular formula: C51H84N16O21
- Molecular weight: 1,257.3 g/mol
- CAS number: 1208243-63-3
- Half-life: Short plasma half life (reported minutes; tissue protective signaling persists longer in models)
- Studied routes: Subcutaneous

## Evidence

- Evidence level: Clinical Trial Evidence
- Highest documented: Controlled human trials
- Human trials: 2
- Controlled human trials: 2
- Preclinical sources: 0
- Latest source: 2017

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Invest Ophthalmol Vis Sci. 2017. 2017. Controlled human trial. Population: Adults with sarcoidosis, small nerve fiber loss and neuropathic pain (n=64) [Source](https://pubmed.ncbi.nlm.nih.gov/28475703/)
2. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2015. 2015. Controlled human trial. Population: Adults with type 2 diabetes and painful neuropathy. Improved HbA1c, lipids and neuropathic symptom scores versus placebo [Source](https://pubmed.ncbi.nlm.nih.gov/25387363/)

## Safety

Side effects: Injection-site reactions; Headache; Trial-stage safety only.

Risks: Not FDA-approved; WADA S0 may apply as non-approved substance.

Human safety basis: Clinical trial reports

Key limitations: Not approved by the FDA for any use..

## Regulatory status

ARA 290 (Cibinetide) has been studied under an Investigational New Drug application. It is not approved for marketing.

- FDA status: Investigational New Drug (IND)
- Availability: Research-Only

## Frequently asked questions

### What is ARA 290 (Cibinetide)?

Helix-B surface peptide (cibinetide) that selectively activates the innate repair receptor without stimulating erythropoiesis. Investigational for small-fiber neuropathy and sarcoidosis.

### How does ARA 290 (Cibinetide) work?

ARA 290, also called cibinetide, is an eleven-amino-acid peptide corresponding to a helix B surface region of erythropoietin. Erythropoietin has two distinct activities: haematopoiesis through the classical EPO receptor homodimer, and tissue protection through a separate heterodimeric innate repair receptor formed by EPOR paired with the beta common receptor CD131.

### Is ARA 290 (Cibinetide) FDA approved?

No. ARA 290 (Cibinetide) is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established. FDA's compounding lists show 503A Category 3: Nominated without adequate support.

### What is the half-life of ARA 290 (Cibinetide)?

Reported half-life for ARA 290 (Cibinetide) is Short plasma half life (reported minutes; tissue protective signaling persists longer in models). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What is the amino acid sequence of ARA 290 (Cibinetide)?

ARA 290 (Cibinetide) has the sequence pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser, giving a chain of 11 amino acids. Its molecular formula is C51H84N16O21.

### What peptides are similar to ARA 290 (Cibinetide)?

Compounds most often compared with ARA 290 (Cibinetide) include Atosiban, B7-33, Carbetocin and Serelaxin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain — Invest Ophthalmol Vis Sci, 2017](https://pubmed.ncbi.nlm.nih.gov/28475703/)
- [ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes — Mol Med, 2015](https://pubmed.ncbi.nlm.nih.gov/25387363/)
- [The time to develop treatments for diabetic neuropathy — Expert Opin Investig Drugs, 2021](https://pubmed.ncbi.nlm.nih.gov/33423557/)
- [Managing fatigue in sarcoidosis - A systematic review of the evidence — Chron Respir Dis, 2017](https://pubmed.ncbi.nlm.nih.gov/27507833/)
- [ARA 290 for treatment of small fiber neuropathy in sarcoidosis — Expert Opin Investig Drugs, 2014](https://pubmed.ncbi.nlm.nih.gov/24555851/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
